



Substitute for form 149B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/622,313
				Filing Date	July 17, 2003
				First Named Inventor	BARDEN, Julian Alexander
				Art Unit	1045 1647
Examiner Name	Unassigned Lockard, J.M.				
Sheet	2	of	2	Attorney Docket Number	080404-000000US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AB	BUELL et al., "Blockade of human P2X ₇ receptor function with a monoclonal antibody," <u>Blood</u> , 92(10):3521-3528 (1998).	<input type="checkbox"/>	<div style="position: relative; height: 300px;"> <div style="position: absolute; top: 0; right: 0; width: 100%; height: 100%; border-left: 2px solid black; border-top: 2px solid black; transform: rotate(45deg);"></div> </div>
	AC	FERRARI et al., "ATP-mediated cytotoxicity in microglial cells," <u>Neuropharmacology</u> , 36(9):1295-1301 (1997).	<input type="checkbox"/>	
	AD	GROSCHER-STEWART et al., "Localisation of P2X ₇ and P2X ₂ receptors by immunohistochemistry in rat stratified squamous epithelia," <u>Cell Tissue Research</u> , 296(3):599-605 (1999).	<input type="checkbox"/>	
	AE	GU et al., "A Glu-496 to ala Polymorphism leads to loss of function of the human P2X ₇ receptor," <u>J. Biol. Chem.</u> , 276:11135-11142 (2001).	<input type="checkbox"/>	
	AF	IP et al., "Dynamics of P2X ₇ receptor pore dilation: pharmacological and functional consequences," <u>Drug Dev. Res.</u> , 53(2/3):60-65 (2001).	<input type="checkbox"/>	
	AG	PENG et al., "P2Z purinoceptor, a special receptor for apoptosis induced by ATP in human leukemic lymphocytes," <u>Chinese Medical Journal</u> , 112(4):356-362 (1999).	<input type="checkbox"/>	
	AH	VIRGILIO et al., "Purinergic P2X ₇ receptor: a pivotal role in inflammation and immunomodulation," <u>Drug Dev. Res.</u> , 45(3/4):207-215 (1998).	<input type="checkbox"/>	
	AI	WILEY et al., "Genetic polymorphisms of the human P2X ₇ receptor and relationship to function," <u>Drug. Dev. Res.</u> , 53(2/3):72-76 (2001).	<input type="checkbox"/>	
	AI	WILEY et al., "A single nucleotide polymorphism is associated with loss of function of the monocyte P2X ₇ receptor," <u>Blood</u> , 96(11 pt 1):abstract 17a (2000).	<input type="checkbox"/>	

Examiner Signature	/Jon Lockard/	Date Considered	10/16/2006
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/622,313
				Filing Date	July 17, 2003
				First Named Inventor	BARDEN, Julian Alexander
				Art Unit	1647
				Examiner Name	Lockard, J. M.
				Attorney Docket Number	080404-000000US
Sheet	2	of	2		

[illegible]

Examiner Signature	/Jon Lockard/	Date Considered	10/16/2006
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.